Home » Newsletters » BioWorld Science

BioWorld Science

May 28, 1998

View Archived Issues

Algene: Q4 and year-end 1997 highlights

CellPro: Q4 and FY 1998 highlights

Neoprobe receives patent allowance for its RIGS/ACT anticancer technology

Xoma granted two patents related to its BPI products

Enzon: Q3 1998 highlights

Glaxo Wellcome updates shareholders at AGM

ImmuLogic licenses antiallergy products from Sankyo

NPS Pharmaceuticals describes new drug development program

Synthelabo and Searle extend joint venture

RSR13 enhances effects of radiotherapy in patients with glioblastoma

PPD and Lilly join forces to develop genitourinary compounds

Multiple-dose pharmacokinetics/pharmacodynamics reported for ABT-761

5-HT4 derivative R-093877 enhances colonic transit in healthy volunteers

FDA says DepoCyt is not approvable

Bombesin receptor antagonists developed by Warner-Lambert

JTE-522 suppresses recurrent allergic inflammation in rats

RCT describes truncated chemokine analogues for rheumatoid arthritis

Antimicrobial peptide isolated from Korean frog

Improved MMR vaccine launched in U.K.

Bayer and Scios enter alliance for Natrecor

Fujisawa presents new cephalosporin with good anti-H. pylori activity

Controlled trial of thalidomide for mucocutaneous lesions of Behcet's syndrome

Phase I results presented for Sch-58500, Schering-Plough's p53-based cancer gene therapy

Ligand files NDA for Panretin gel

p38 kinase inhibitor protects against ischemic cell death in preclinical model

Glaxo Wellcome and NeXstar sign three-part collaboration; NeXstar in-licenses topo I inhibitor

Profile of antiarrhythmic activity of GYKI-16638, a new class Ib/III agent

New HIV protease inhibitors disclosed by Merck & Co.

P2T purinoceptor receptor antagonists with platelet antiaggregatory activity

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 12, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 12, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
CTAD 2025: The challenges of combination therapies for dementia
BioWorld Science
At the Clinical Trials on Alzheimer’s Disease 2025 meeting, a panel of experts discussed the need for developing combination therapies for the complex diseases...
DEE-lightful: Praxis’ phase II results allow stock to flex its muscle
BioWorld
Positive efficacy results led to Praxis Precision Medicines Inc.’s phase II Embold study in developmental and epileptic encephalopathies (DEEs) being halted...